Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome

Omar S. Khwaja, Eugenia Ho, Katherine V. Barnes, Heather M. O'Leary, Luis M. Pereira, Yaron Finkelstein, Charles A. Nelson, Vanessa Vogel-Farley, Geneva DeGregorio, Ingrid A. Holm, Umakanth Khatwa, Kush Kapur, Mark E. Alexander, Deirdre M. Finnegan, Nicole G. Cantwell, Alexandra C. Walco, Leonard Rappaport, Matt Gregas, Raina N. Fichorova, Michael W. ShannonMriganka Sur, Walter E. Kaufmann

Research output: Contribution to journalArticle

Abstract

Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder mainly affecting females and is associated with mutations in MECP2, the gene encoding methyl CpG-binding protein 2. Mouse models suggest that recombinant human insulinlike growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve many clinical features. We evaluated the safety, tolerability, and pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 mutations (9 with RTT). In addition, we performed a preliminary assessment of efficacy using automated cardiorespiratory measures, EEG, a set of RTT-oriented clinical assessments, and two standardized behavioral questionnaires. This phase 1 trial included a 4-wk multiple ascending dose (MAD) (40-120 μg/kg twice daily) period and a 20-wk open-label extension (OLE) at the maximum dose. Twelve subjects completed the MAD and 10 the entire study, without evidence of hypoglycemia or serious adverse events. Mecasermin reached the CNS compartment as evidenced by the increase in cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug followed nonlinear kinetics, with greater distribution in the peripheral compartment. Cardiorespiratory measures showed that apnea improved during the OLE. Some neurobehavioral parameters, specifically measures of anxiety and mood also improved during the OLE. These improvements in mood and anxiety scores were supported by reversal of right frontal alpha band asymmetry on EEG, an index of anxiety and depression. Our data indicate that IGF-1 is safe and well tolerated in girls with RTT and, as demonstrated in preclinical studies, ameliorates certain breathing and behavioral abnormalities.

Original languageEnglish (US)
Pages (from-to)4596-4601
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number12
DOIs
StatePublished - Mar 25 2014
Externally publishedYes

Fingerprint

Rett Syndrome
Intercellular Signaling Peptides and Proteins
Pharmacokinetics
Safety
Anxiety
Electroencephalography
Methyl-CpG-Binding Protein 2
Mutation
Apnea
Therapeutics
Hypoglycemia
Cerebrospinal Fluid
Respiration
Depression
mecasermin
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • General

Cite this

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. / Khwaja, Omar S.; Ho, Eugenia; Barnes, Katherine V.; O'Leary, Heather M.; Pereira, Luis M.; Finkelstein, Yaron; Nelson, Charles A.; Vogel-Farley, Vanessa; DeGregorio, Geneva; Holm, Ingrid A.; Khatwa, Umakanth; Kapur, Kush; Alexander, Mark E.; Finnegan, Deirdre M.; Cantwell, Nicole G.; Walco, Alexandra C.; Rappaport, Leonard; Gregas, Matt; Fichorova, Raina N.; Shannon, Michael W.; Sur, Mriganka; Kaufmann, Walter E.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 12, 25.03.2014, p. 4596-4601.

Research output: Contribution to journalArticle

Khwaja, OS, Ho, E, Barnes, KV, O'Leary, HM, Pereira, LM, Finkelstein, Y, Nelson, CA, Vogel-Farley, V, DeGregorio, G, Holm, IA, Khatwa, U, Kapur, K, Alexander, ME, Finnegan, DM, Cantwell, NG, Walco, AC, Rappaport, L, Gregas, M, Fichorova, RN, Shannon, MW, Sur, M & Kaufmann, WE 2014, 'Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 12, pp. 4596-4601. https://doi.org/10.1073/pnas.1311141111
Khwaja, Omar S. ; Ho, Eugenia ; Barnes, Katherine V. ; O'Leary, Heather M. ; Pereira, Luis M. ; Finkelstein, Yaron ; Nelson, Charles A. ; Vogel-Farley, Vanessa ; DeGregorio, Geneva ; Holm, Ingrid A. ; Khatwa, Umakanth ; Kapur, Kush ; Alexander, Mark E. ; Finnegan, Deirdre M. ; Cantwell, Nicole G. ; Walco, Alexandra C. ; Rappaport, Leonard ; Gregas, Matt ; Fichorova, Raina N. ; Shannon, Michael W. ; Sur, Mriganka ; Kaufmann, Walter E. / Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 12. pp. 4596-4601.
@article{8eafefe8359d47fb8ecfcb939f4b9f41,
title = "Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome",
abstract = "Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder mainly affecting females and is associated with mutations in MECP2, the gene encoding methyl CpG-binding protein 2. Mouse models suggest that recombinant human insulinlike growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve many clinical features. We evaluated the safety, tolerability, and pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 mutations (9 with RTT). In addition, we performed a preliminary assessment of efficacy using automated cardiorespiratory measures, EEG, a set of RTT-oriented clinical assessments, and two standardized behavioral questionnaires. This phase 1 trial included a 4-wk multiple ascending dose (MAD) (40-120 μg/kg twice daily) period and a 20-wk open-label extension (OLE) at the maximum dose. Twelve subjects completed the MAD and 10 the entire study, without evidence of hypoglycemia or serious adverse events. Mecasermin reached the CNS compartment as evidenced by the increase in cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug followed nonlinear kinetics, with greater distribution in the peripheral compartment. Cardiorespiratory measures showed that apnea improved during the OLE. Some neurobehavioral parameters, specifically measures of anxiety and mood also improved during the OLE. These improvements in mood and anxiety scores were supported by reversal of right frontal alpha band asymmetry on EEG, an index of anxiety and depression. Our data indicate that IGF-1 is safe and well tolerated in girls with RTT and, as demonstrated in preclinical studies, ameliorates certain breathing and behavioral abnormalities.",
author = "Khwaja, {Omar S.} and Eugenia Ho and Barnes, {Katherine V.} and O'Leary, {Heather M.} and Pereira, {Luis M.} and Yaron Finkelstein and Nelson, {Charles A.} and Vanessa Vogel-Farley and Geneva DeGregorio and Holm, {Ingrid A.} and Umakanth Khatwa and Kush Kapur and Alexander, {Mark E.} and Finnegan, {Deirdre M.} and Cantwell, {Nicole G.} and Walco, {Alexandra C.} and Leonard Rappaport and Matt Gregas and Fichorova, {Raina N.} and Shannon, {Michael W.} and Mriganka Sur and Kaufmann, {Walter E.}",
year = "2014",
month = "3",
day = "25",
doi = "10.1073/pnas.1311141111",
language = "English (US)",
volume = "111",
pages = "4596--4601",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "12",

}

TY - JOUR

T1 - Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome

AU - Khwaja, Omar S.

AU - Ho, Eugenia

AU - Barnes, Katherine V.

AU - O'Leary, Heather M.

AU - Pereira, Luis M.

AU - Finkelstein, Yaron

AU - Nelson, Charles A.

AU - Vogel-Farley, Vanessa

AU - DeGregorio, Geneva

AU - Holm, Ingrid A.

AU - Khatwa, Umakanth

AU - Kapur, Kush

AU - Alexander, Mark E.

AU - Finnegan, Deirdre M.

AU - Cantwell, Nicole G.

AU - Walco, Alexandra C.

AU - Rappaport, Leonard

AU - Gregas, Matt

AU - Fichorova, Raina N.

AU - Shannon, Michael W.

AU - Sur, Mriganka

AU - Kaufmann, Walter E.

PY - 2014/3/25

Y1 - 2014/3/25

N2 - Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder mainly affecting females and is associated with mutations in MECP2, the gene encoding methyl CpG-binding protein 2. Mouse models suggest that recombinant human insulinlike growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve many clinical features. We evaluated the safety, tolerability, and pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 mutations (9 with RTT). In addition, we performed a preliminary assessment of efficacy using automated cardiorespiratory measures, EEG, a set of RTT-oriented clinical assessments, and two standardized behavioral questionnaires. This phase 1 trial included a 4-wk multiple ascending dose (MAD) (40-120 μg/kg twice daily) period and a 20-wk open-label extension (OLE) at the maximum dose. Twelve subjects completed the MAD and 10 the entire study, without evidence of hypoglycemia or serious adverse events. Mecasermin reached the CNS compartment as evidenced by the increase in cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug followed nonlinear kinetics, with greater distribution in the peripheral compartment. Cardiorespiratory measures showed that apnea improved during the OLE. Some neurobehavioral parameters, specifically measures of anxiety and mood also improved during the OLE. These improvements in mood and anxiety scores were supported by reversal of right frontal alpha band asymmetry on EEG, an index of anxiety and depression. Our data indicate that IGF-1 is safe and well tolerated in girls with RTT and, as demonstrated in preclinical studies, ameliorates certain breathing and behavioral abnormalities.

AB - Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder mainly affecting females and is associated with mutations in MECP2, the gene encoding methyl CpG-binding protein 2. Mouse models suggest that recombinant human insulinlike growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve many clinical features. We evaluated the safety, tolerability, and pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 mutations (9 with RTT). In addition, we performed a preliminary assessment of efficacy using automated cardiorespiratory measures, EEG, a set of RTT-oriented clinical assessments, and two standardized behavioral questionnaires. This phase 1 trial included a 4-wk multiple ascending dose (MAD) (40-120 μg/kg twice daily) period and a 20-wk open-label extension (OLE) at the maximum dose. Twelve subjects completed the MAD and 10 the entire study, without evidence of hypoglycemia or serious adverse events. Mecasermin reached the CNS compartment as evidenced by the increase in cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug followed nonlinear kinetics, with greater distribution in the peripheral compartment. Cardiorespiratory measures showed that apnea improved during the OLE. Some neurobehavioral parameters, specifically measures of anxiety and mood also improved during the OLE. These improvements in mood and anxiety scores were supported by reversal of right frontal alpha band asymmetry on EEG, an index of anxiety and depression. Our data indicate that IGF-1 is safe and well tolerated in girls with RTT and, as demonstrated in preclinical studies, ameliorates certain breathing and behavioral abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=84896912072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896912072&partnerID=8YFLogxK

U2 - 10.1073/pnas.1311141111

DO - 10.1073/pnas.1311141111

M3 - Article

C2 - 24623853

AN - SCOPUS:84896912072

VL - 111

SP - 4596

EP - 4601

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 12

ER -